Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation

Next Previous
Search
Trial Profile

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NT 112 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca; Neogene Therapeutics

Most Recent Events

  • 27 Apr 2025 Planned End Date changed from 30 Aug 2040 to 29 Aug 2042.
  • 27 Apr 2025 Status changed from recruiting to active, no longer recruiting.
  • 24 Dec 2024 Planned End Date changed from 2 Jan 2040 to 30 Aug 2040.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top